Case History (George Schroth, MD) The patient was a 49-year-old white woman with a history of essential hypertension and hypercholesterolemia and an unclear history of a stroke or aneurysm who presented after 2 days of intermittent, severe chest pressure associated with a severe headache. The symptoms had returned at 9:00 A.M. and were still present 2 hours later on presentation to the emergency department. No visual changes were reported. The patient complained of nausea but not dyspnea. She had no past history of chest pain, coronary artery disease, or myocardial infarction. Her risk factors for coronary atherosclerosis consisted of hypertension, hypercholesterolemia, obesity, and a 20-pack-year history of smoking. There was no family history of heart disease. The patient was taking her antihypertensive medication, which consisted of verapamil, triamterene, and hydrochlorothiazide, as prescribed.
The patient's previous history of cerebral aneurysm was unclear. It was associated with what the patient described as a "stroke" several years previously. A cholecystectomy had been performed 8 months previously. There was no history of alcohol or illicit drug use. She had no known allergies.
Physical Examination The patient was an overweight, middle-aged white woman who was fully alert and oriented but in mild distress. She was afebrile with a blood pressure of 116/68 mm Hg; pulse, 80; and respirations, 16 . Cardiac monitoring revealed intermittent complete atrioventricular (AV) dissociation. The patient's pupils were equal, round, and reactive to light; her extraocular muscles were intact; and conjunctivae were normal. Examination of the fundi revealed normal disc margins without hemorrhages, but arteriovenous nicking was apparent bilaterally. No Roth's spots were seen. Her oropharynx was without erythema, exudate, or petechiae. The patient's neck was supple and without adenopathy. Thyroid gland examination was normal. Carotid upstrokes Clinicopathological Conference presented at The University of Texas Medical School at Houston on June 21, 1993. Correspondence to Dr Buja, were brisk bilaterally and without bruits. Jugular venous distention was not noted. The chest was clear to auscultation. On cardiovascular examination, there was no displacement of the apex beat, and the precordium was not hyperdynamic to inspection. There were no lifts or heaves. S, and S2 were normal. An S4 was heard, but there was no S3. No murmurs or rubs were noted. Peripheral pulses were 2+ throughout. Abdominal examination revealed a soft and nontender abdomen with normal bowel sounds. No hepatosplenomegaly was noted, and no bruits were heard. The rectal examination was guaiac negative. The patient had no cyanosis, clubbing, or edema of her extremities. There was no evidence of Janeway lesions, Osler's nodes, or splinter hemorrhages. No femoral bruits were heard. The neurological examination demonstrated no focal abnormalities.
On admission, the ECG (Fig 1) showed normal sinus rhythm with first-degree AV block, ST segment elevation with Q-waves, and T-wave inversion in leads II, III, aVF, and V4, Vs, and V6. Right-sided chest leads showed ST segment elevation in RV4, RV5, and RV6. ST depression was noted in leads V1 3, I, and aVL. ECG monitoring revealed intermittent Mobitz type II and complete heart block.
Hospital Course The patient was admitted with a diagnosis of acute inferolateral myocardial infarction with right ventricular involvement. An extensive workup generated comprehensive chemical analyses (Table 1) . Because of her history of possible cerebral aneurysm, she was not treated with intravenous thrombolysis, and an emergency computed tomography (CT) scan of the head did not demonstrate any evidence of intracranial bleeding. Because of ongoing chest discomfort and AV dissociation, the patient was taken to the catheterization laboratory.
Left coronary angiography demonstrated a normal left main coronary artery. The left anterior descending coronary artery was noted to have severe diffuse distal disease. The circumflex artery demonstrated no significant narrowing. The right coronary artery was completely occluded just after the first acute marginal branch. The left ventricle was noted to have severe inferior hypokinesis. After primary percutaneous transluminal coronary angioplasty (PTCA) (performed at 3:00 P.M.) followed by 250 000 U urokinase (Fig 2) , a second lesion was identified distally. This lesion was also dilated, and at the end of the procedure the patient had good right coronary flow. There During the procedure, the patient had persisting severe hypotension that required extensive volume resuscitation with intravenous saline, support with intravenous dopamine, insertion of a temporary pacemaker, and intra-aortic balloon pump counterpulsation. Hemodynamics at the end of the procedure were stable.
The patient was then taken to the coronary care unit. The heparin infusion that had been started in the catheterization laboratory was continued. By 8:30 P.M., the dopamine infusion was discontinued. By that time, the blood pressure was 130/80 mm Hg; pulse, 100; and pulmonary artery pressure, 37/22 mm Hg. Intra-aortic balloon pump support was continued, and the patient did well throughout the night. treated with 0.5 mg atropine IV, and normal sinus rhythm returned. Later that day, the intra-aortic balloon pump, Swan-Ganz catheter, and temporary pacer were removed. At midnight, the patient developed chest discomfort that was graded 7/10 in severity. Her physical examination was unchanged from earlier in the day. The monitor demonstrated a Mobitz type I block. ECG was unchanged. The patient's blood pressure was 94/51 mm Hg; pulse, 70; and respirations, 18. She was given sublingual nitroglycerin three times with partial relief of her pain. Thirty minutes later, the patient again was noted to be in AV dissociation. The chest discomfort continued, and the patient was given 2 mg morphine IV. The partial thromboplastin time drawn before this episode suggested that the patient was not adequately anticoagulated; she therefore was given supplemental heparin, and her chest discomfort subsided shortly thereafter.
During the patient's third hospital day, the ECG was essentially unchanged from the previous day. New What Happened?
The presence of heart sounds and a palpable pressure rule out sudden electromechanical dissociation as the cause of death. Pulmonary embolism is rare in patients with myocardial infarction who have been treated with heparin and aspirin and brief bedrest. There was no indication of cerebral or femoral bleeding. No medications had been given. A diagnosis of myocardial rupture is suggested by the suddenness of the event, by the fact that the heart sounds became distant, and by the absence of chest discomfort. However, these features cannot confidently exclude (1) infarction in a new territory (that of the distal left anterior descending coronary artery, which was diseased) or (2) extension of the previous infarction by hemorrhage into the wall of the ventricle, by rethrombosis of the right coronary artery, or by hemorrhage into the wall of the artery. The recurrence of complete heart block is not a very helpful sign as this could occur from recurrent ischemia to the AV node or vagal discharge (the latter is well characterized in experimental acute pericardial tamponade and is consistent with the response to atropine). It is unlikely that reocclusion of the right coronary artery would by itself precipitate a nonarrhythmic fatality because that territory was already infarcted. The ejection fraction on day 1 (before therapy, when the right coronary artery was occluded proximally, the ST segments were elevated, and large Q-waves were present) was not very depressed (57%). Thus, reocclusion of the right coronary artery could not have caused sudden heart failure. Therefore, it is likely that this patient suffered myocardial rupture, with or without new myocardial necrosis due to hemorrhage or to occlusion of either the right or left anterior descending coronary artery.
Myocardial rupture occurs in only 2% to 3% of myocardial infarcts, but because it is an almost uniformly fatal event, it accounts for 10% to 30% of infarct fatalities. The patients at particularly high risk are those with a large, Q-wave anterior or apical infarct and no prior infarct,1-4 as previous infarction results in collaterals (which limit the size and transmural extent of the infarct)5 and in scar (which provides structural support). It is likely that rupture is preceded by infarct expansion (the acute stretching and thinning of the infarcted tissue that is due to transmural myocardial necrosis and lysis of collagen) and promoted by increased afterload. Expansion is distinguished from extension as the former does not involve new necrosis.6 Rupture may be made more likely by late (12 to 24 hours) thrombolytic therapy.7 This patient had chest discomfort for 2 days before admission, at which time she had Q-waves and an elevation in lactate dehydrogenase (Table 2) . Rupture tends to occur between days 4 and 7, and this too applies to her case, as does the fact that women are at greater risk of rupture.8 Finally, inferior infarction with right ventricular involvement carries a threefold to fourfold greater risk of rupture than infarction restricted to the inferior wall.9 Thus, in this woman whose first infarct was large and transmural, involved the right ventricle, and was treated by late thrombolytic therapy, the sudden development of hypotension and heart block on the fourth hospital day (infarct day 5 or 6) is likely to be due to rupture of the heart. Where Was the Rupture?
It could have involved the septum, causing an acute ventricular septal defect, but in general this would be accompanied by a new murmur and thrill, and these patients are likely to survive long enough to be diagnosed and have emergency surgery. Thus, this patient probably had a rupture of the apex or the inferior or posterior free wall.
Reperfusion by thrombolytic agents probably causes some oxidative injury and often converts an anemic infarct into a hemorrhagic infarct.1"'0 Overall, the risk of rupture appears to be slightly increased by thrombolytic therapy3 (more so if begun after 12 The diagnosis was made promptly. The differential diagnosis in a middle-aged hypertensive woman with no previous history of coronary symptoms who presents with chest discomfort and headache includes hypertensive crisis, aortic dissection, pulmonary embolus, myocarditis, pericarditis, and uncommon presentations of cervical spinal disease or cerebral hemorrhage with secondary myocardial ischemia. However, the ECG was diagnostic of an inferoapical and right ventricular infarction. The underlying problem is almost always rupture of, or hemorrhage into, an atherosclerotic coronary plaque followed by occlusive thrombosis. A minority of cases are precipitated by development of thrombosis on an ulcerated plaque or primary vasospasm. In general, vasoconstriction is a secondary complication of plaque hemorrhage and thrombosis.13 '14 Rarely, such presentation is due to (1) dissection of a right coronary artery in a setting of a proximal aortic dissection, (2) arteritis or myocarditis, (3) a coronary anomaly or thromboembolism from the left atrium or from a patent foramen ovale, or (4) Although stroke can be a complication of myocardial infarction-particularly from thrombosis at the site of a transmural apical infarct and occasionally due to showers of emboli from the left atrium or ventricle, hypertensive crisis, or proximal aortic dissection-stroke complicates only 1% of myocardial infarctions.1 The diagnosis is more likely with a headache or history of aneurysms but usually present with a focal neurological sign (or, in the case of hemorrhage, with confusion, obtundation, or neck stiffness). Thus, the CT scan was unlikely to reveal a contraindication to thrombolytic therapy.
The CT scan delayed catheterization by 1 or 2 hours, a situation that might have resulted anyway had the catheterization laboratory not been immediately available. The delay was probably not a severe problem if the patient's symptoms and ST segments had largely resolved in response to nitroglycerin, narcotic, oxygen, sedation, rest (for example, deferring the rectal examination, using stool softeners to prevent straining [note that she decompensated on the commode], and testing stools for occult blood), aspirin, and reassurance.14 Moreover, the benefits of acute recanalization of the artery are much smaller both when therapy is begun late (in this case the infarct was at least 4 An intra-aortic balloon was also placed. This probably reduced ischemia of the septum, which contributes importantly to right ventricular function, maintained perfusion pressure to the right coronary artery (in the face of the patient's recurrent hypotension), and helped correct her metabolic acidosis.26 As I will discuss, this patient also required primary angioplasty as opposed to intravenous thrombolytic treatment for her infarction. Thus, a case can be made (in retrospect, of course) for deferring the CT scan and going directly to the cardiac catheterization laboratory.
It is not mentioned whether the patient had been taking aspirin. If In theory, titration of bleeding times (which are shortened to 3 minutes in acute myocardial infarction) might be helpful, but no studies have addressed this. It is important to block the platelets and the coagulation enzymes before administering thrombolytic therapy because plasmin activates both systems and so is thrombogenic as well as thrombolytic. 33 Magnesium should be administered because of the patient's low (1.5 mg/dL) serum level. Even in patients with normal levels, magnesium decreases platelet aggregation, peripheral vascular resistance, heart rate, calcium entry, and ventricular arrhythmias.34 Only extremely high doses cause heart block or significant hypotension. Several trials have documented a 20% to 50% reduction in acute myocardial infarction mortality using 8 mmol MgSO4 IV over 5 minutes followed by 65 mmol over 24 hours. The ISIS-4 Trial will study the effects of magnesium in combination with thrombolytic therapy and captopril on both early and late mortality. 34 Should This Patient Have Undergone Urgent Recanalization?
Her symptoms began 2 days before admission, and her white blood cell count and levels of creatine kinase and lactate dehydrogenase were clearly elevated on the day of admission, which is consistent with 1 to 2 days of ongoing necrosis. It is clear that there is no benefit of thrombolytic therapy after 24 hours of infarct symptoms.11,12,35 However, the patient's symptoms were intermittent, and on presentation she had 2 more hours of pain and still had some R-wave and ST elevation in leads II, III, aVF, Vs, and V6, suggesting that some myocardium could be salvaged. Treatment of acute myocardial infarction with thrombolytic therapy begun 2 to 6 hours after the onset of symptoms yields 30% and 20% reductions, respectively, in mortality.12 Furthermore, treatment begun as late as 12 hours after symptom onset prevents late ventricular dilation ("remodeling") even though it does not reduce infarct size. This is associated with about a 15% reduction in mortality. These late net benefits are obtained despite a small increase in risk of death during the first 24 hours after late thrombolytic therapy. These deaths are the result of heart failure, ventricular rupture, or electromechanical dissociation (for review, see Reference 12) . The usefulness of late thrombolytic therapy in the subset of patients with inferior infarction extending to the right ventricle is not known. However, in a recent series of patients with inferior infarction, 54% of whom also had right ventricular infarction, thrombolytic therapy begun a mean of 6 hours after symptom onset was associated with a 71% lower mortality.9 It is noteworthy that even though right ventricular involvement in inferior myocardial infarction confers a fivefold increased risk of in-hospital mortality (compared with patients with inferior myocardial infarction without right ventricular involvement), late prognoses are almost identical. Right ventricular infarction is accompanied by profound hypokinesis with remarkable spontaneous improvement -to a near-normal range in most patients. Because the right ventricle is so thin, it seems to survive in a hibernating state, probably by diffusion of oxygen from the right ventricular cavity. Even late thrombolytic therapy is probably helpful for right ventricular function. 36 mortality difference was seen in the GISSI trial.40 In the recent PAMI trial, women with acute myocardial infarction randomized to PTCA had a 4% mortality rate versus a 14% mortality rate for treatment with t-PA. 41 In this patient's case, the possibility that the CT scan had missed an aneurysm or stroke-in-evolution was another reason to choose primary PTCA rather than thrombolytic therapy. What Is the Rationale for Urokinase After Angioplasty?
Major trials have indicated that the routine use of angioplasty following thrombolytic therapy results in higher mortality.42 There are some data justifying the widespread practice of using urokinase after angioplasty. In one small trial,43 the routine use of urokinase after elective angioplasty was associated with a nonsignificant 50% reduction in the risk of acute occlusion or Q-wave infarction. In a small retrospective study of the administration of urokinase following direct PTCA for patients who presented with acute myocardial infarction within 6 hours of symptom onset (or 24 hours with intermittent symptoms), there was a marked reduction in the rate of restenosis at 1 month. 44 In this patient's case, urokinase was obviously given because of the angiographic evidence of thrombosis. Indeed, after urokinase administration, the thrombus was lysed, and a more distal stenosis became apparent. However, the use of urokinase 6 to 48 hours after infarction probably has hazards as well. The conversion from bland to hemorrhagic infarct and the increased risk of rupture, as noted above, may have several mechanisms. Fibrin within the infarcted myocardium serves as a scaffold for fibroblast proliferation and for the elaboration of a collagen scar. In cases of severe necrosis, the cross-linked fibrin may be the only source of structural support. Moreover, plasmin cleaves more than fibrin. It proteolytically activates collagenase and elastase and thus may actively degrade the infarct tissue.45 One approach to avoiding the risks of post-PTCA lytic therapy would be to administer it selectively to the arterial wall, via a perfusion catheter. In the present case, however, urokinase was not given for mural thrombus but rather for complete occlusion. Presumably the intracoronary infusion was discontinued as soon as recanalization occurred so as not to irrigate the infarct with more plasminogen activator. At any rate, the urokinase and second PTCA achieved not only a patent artery but also, more important, good flow-presumably TIMI III flow, which confers a better prognosis than TIMI II flow (a patent artery with slow flow, presumably due to downstream emboli, aggregates of platelets or leukocytes, and vasospasm; see Reference 12).
On the second hospital day, the patient experienced recurrent chest discomfort. After angioplasty and thrombolytic therapy, the recurrence of symptoms in the patient on heparin and aspirin should at least raise the question of hemorrhage into the wall of the coronary. In this patient's case, the partial thromboplastin time was astutely checked and found to be low, and the symptoms resolved with increased heparin. Had the partial thromboplastin time not been low, repeat catheterization and possible repeat angioplasty or placement of an intracoronary stent would have been indicated.
On day 3, the patient developed an apparent pericardial rub and a soft systolic ejection murmur at the left sternal border. The rub is expected with a Q-wave infarction, but the location of the murmur suggests that it could not be attributed to dysfunction of the posterior papillary muscle. This would have raised some concern about the possibility of a ventricular septal defect. Presumably the echo, which noted inferoposterolateral and distal right ventricular akinesis and a small effusion, did not detect evidence of mitral regurgitation, ventricular septal defect, pseudoaneurysm, severe wall thinning, or left ventricular enlargement. In general, it is reasonable to start captropril at about this time (day 4 or 5 after infarction) to reduce the chance of late ventricular enlargement, heart failure, and death. However, the benefits of captropril can probably be obtained when it is begun several weeks after infarction46 and need not be started when the patient is hemodynamically unstable. There is in any case some question as to whether women benefit from captropril in this setting. 47 On day 4 when the patient suddenly developed dyspnea and shock, the chances of survival were extremely low. From a broader perspective, it would of course have been better had this patient not been a smoker and had she been able to moderate her hypertension, hypercholesterolemia, and obesity by dietary means. It might also have saved her life had she sought medical attention during the first few hours of her chest discomfort. Finally, she probably would have benefited from taking aspirin and replacement estrogens, despite the history of hypertension, smoking, and questionable history of (Collagen, together with the myocyte motor endplates, gives the heart its tensile strength.) Transmural myocardial necrosis, inflammation and associated lysis of collagen; increased left ventricular afterload; and late reperfusion influence infarct expansion.6'1054-57
Obviously, there might be some benefit to inhibiting collagen degradation, although a study in the rat58 showed no benefit. Transforming growth factor-a (TGF-/3) is reported to decrease experimental infarct size.59 TGF-f stimulates collagen synthesis. However, the early benefits in these models may be attributable to the antiinflammatory effect of TGF-/3, which may reduce free radical injury. A remarkable reduction in infarct size has also been described from the infusion of basic fibroblast growth factor (FGF) after experimental coronary ligation. Basic FGF60 inhibits collagen syntheSiS61 but is a well known promoter of angiogenesis,62 a process that takes several days. The 
